Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

immunovant inc - IMVT

IMVT

Close Chg Chg %
29.10 -0.69 -2.37%

Closed Market

28.41

-0.69 (2.37%)

Volume: 641.44K

Last Updated:

Oct 23, 2026, 4:00 PM EDT

Trade Now

Company Overview: immunovant inc - IMVT

IMVT Key Data

Open

$28.93

 Day Range

28.15 - 28.93

52 Week Range

18.74 - 45.35

 Market Cap

$5.86B

Shares Outstanding

206.55M

 Public Float

84.83M

Beta

0.84

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.81

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.46M

  

IMVT Performance

1 Week
 
 6.29%
 
1 Month
 
 -14.68%
 
3 Months
 
 -27.91%
 
1 Year
 
 50.00%
 
5 Years
 
 253.36%
 

IMVT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About immunovant inc - IMVT

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.

IMVT At a Glance

Immunovant, Inc.
1000 Park Forty Plaza
Durham, North Carolina 27713
Phone 1-917-410-3120 Revenue 0.00
Industry Biotechnology Net Income -505,606,000.00
Sector Health Technology Employees 315
Fiscal Year-end 03 / 2027
View SEC Filings

IMVT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 5.942
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -6.816
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.00

IMVT Efficiency

Revenue/Employee N/A
Income Per Employee -1,605,098.413
Receivables Turnover N/A
Total Asset Turnover N/A

IMVT Liquidity

Current Ratio 9.086
Quick Ratio 9.086
Cash Ratio 8.639

IMVT Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -58.287
Return on Equity -64.82
Return on Total Capital -59.297
Return on Invested Capital -64.82

IMVT Capital Structure

Total Debt to Total Equity 0.008
Total Debt to Total Capital 0.008
Total Debt to Total Assets 0.008
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Immunovant Inc - IMVT

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
1.32M 231.00K 377.00K 409.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.32M 231.00K 377.00K 409.00K
Depreciation
1.32M 231.00K 377.00K 409.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+7.47% -82.55% +63.20% +8.49%
Gross Income
(1.32M) (231.00K) (377.00K) (409.00K)
Gross Income Growth
-7.47% +82.55% -63.20% -8.49%
Gross Profit Margin
- - - -
-
2023 2024 2025 2026 5-year trend
SG&A Expense
206.95M 269.98M 437.77M 532.49M
Research & Development
160.26M 212.93M 360.92M 456.66M
Other SG&A
46.70M 57.05M 76.86M 75.83M
SGA Growth
+33.69% +30.45% +62.15% +21.64%
Other Operating Expense
- - - -
-
Unusual Expense
- - 10.00M 12.50M
-
EBIT after Unusual Expense
(218.28M) (282.71M) (438.15M) (532.90M)
Non Operating Income/Expense
7.33M 23.94M 25.20M 27.51M
Non-Operating Interest Income
7.58M 24.95M 24.73M 25.33M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(210.95M) (258.77M) (412.95M) (505.39M)
Pretax Income Growth
-34.52% -22.67% -59.58% -22.39%
Pretax Margin
- - - -
-
Income Tax
9.00K 567.00K 891.00K 215.00K
Income Tax - Current - Domestic
9.00K 567.00K 891.00K 215.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(210.96M) (259.34M) (413.84M) (505.61M)
Minority Interest Expense
- - - -
-
Net Income
(210.96M) (259.34M) (413.84M) (505.61M)
Net Income Growth
-34.60% -22.93% -59.58% -22.17%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(210.96M) (259.34M) (413.84M) (505.61M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(210.96M) (259.34M) (413.84M) (505.61M)
EPS (Basic)
-1.7141 -1.8779 -2.7303 -2.7716
EPS (Basic) Growth
-19.95% -9.56% -45.39% -1.51%
Basic Shares Outstanding
123.08M 138.10M 151.57M 182.42M
EPS (Diluted)
-1.7141 -1.8779 -2.7303 -2.7716
EPS (Diluted) Growth
-19.95% -9.56% -45.39% -1.51%
Diluted Shares Outstanding
123.08M 138.10M 151.57M 182.42M
EBITDA
(206.95M) (269.98M) (437.77M) (532.49M)
EBITDA Growth
-33.69% -30.45% -62.15% -21.64%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 48.875
Number of Ratings 17 Current Quarters Estimate -0.729
FY Report Date 12 / 2026 Current Year's Estimate -2.936
Last Quarter’s Earnings -0.754 Median PE on CY Estimate N/A
Year Ago Earnings -2.77 Next Fiscal Year Estimate -2.919
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 15 15
Mean Estimate -0.73 -0.73 -2.94 -2.92
High Estimates -0.53 -0.59 -2.52 -2.16
Low Estimate -0.80 -0.84 -3.17 -3.35
Coefficient of Variance -11.01 -11.78 -6.92 -12.72

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 12
OVERWEIGHT 0 0 0
HOLD 4 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Insider Actions for Immunovant Inc - IMVT

Date Name Shares Transaction Value
Oct 12, 2026 Jay S. Stout Chief Technology Officer 203,128 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.06 per share 6,512,283.68
Oct 12, 2026 Jay S. Stout Chief Technology Officer 201,532 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.06 per share 6,461,115.92
Oct 12, 2026 Melanie Gloria Chief Operating Officer 217,060 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.06 per share 6,958,943.60
Oct 12, 2026 Christopher A. van Tuyl Chief Legal Officer 175,218 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.06 per share 5,617,489.08
Oct 6, 2026 Eric Venker Chief Executive Officer; Director 346,467 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $14.46 per share 5,009,912.82
Oct 6, 2026 Eric Venker Chief Executive Officer; Director 260,581 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $33.65 per share 8,768,550.65
Oct 6, 2026 Eric Venker Chief Executive Officer; Director 257,075 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.11 per share 8,768,828.25
Oct 6, 2026 Eric Venker Chief Executive Officer; Director 921,875 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Immunovant Inc in the News